An analytical study by Merck & Co revealed the use of Ivermectin to treat Covid-19 does not pass safety and efficacy standards. Ivermectin is an anti-parasite drug, which Merck developed in partnership with the Kitasato Institute of Japan. The objective of the...
Merck & Co. (NYSE:MRK) has signed a $356 million supply deal with the US government for the supply of 60,000 to 100,000 doses of its investigational severe COVID-19 treatment. This adds to the government’s arsenal of possible COVID-19 therapies and also that large...
